GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Olink Holding AB (NAS:OLK) » Definitions » ROCE %

Olink Holding AB (Olink Holding AB) ROCE % : -7.09% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Olink Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Olink Holding AB's annualized ROCE % for the quarter that ended in Dec. 2023 was -7.09%.


Olink Holding AB ROCE % Historical Data

The historical data trend for Olink Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olink Holding AB ROCE % Chart

Olink Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
-4.08 -0.18 -9.81 -3.14 -7.91

Olink Holding AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.57 -14.38 -8.05 -1.54 -7.09

Olink Holding AB ROCE % Calculation

Olink Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-39.047/( ( (476.29 - 36.087) + (602.252 - 55.487) )/ 2 )
=-39.047/( (440.203+546.765)/ 2 )
=-39.047/493.484
=-7.91 %

Olink Holding AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-37.62/( ( (552.825 - 38.697) + (602.252 - 55.487) )/ 2 )
=-37.62/( ( 514.128 + 546.765 )/ 2 )
=-37.62/530.4465
=-7.09 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Olink Holding AB  (NAS:OLK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Olink Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of Olink Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Olink Holding AB (Olink Holding AB) Business Description

Traded in Other Exchanges
Address
Uppsala Science Park, Uppsala, SWE, SE-75183
Olink Holding AB has a proprietary and patented Proximity Extension Assay technology, which enables researchers to use one platform for discovery to clinical trials to diagnostic applications utilizing the established infrastructure of labs and installed instrumentation. It has two segments including Kit and Services. It derives revenues from Sweden, the Americas, China, EMEA (Excluding Sweden) Japan, and other regions.